These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


322 related items for PubMed ID: 33931929

  • 1. Diagnostic accuracy of 68 Ga-PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen.
    Coşar U, Şen İ, Aydos U, Koparal MY, Uçar M, Tokgöz N, Gönül İI, Akdemir ÜÖ, Atay LÖ, Sözen TS.
    Int J Clin Pract; 2021 Aug; 75(8):e14287. PubMed ID: 33931929
    [Abstract] [Full Text] [Related]

  • 2. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.
    Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [Abstract] [Full Text] [Related]

  • 3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
    Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [Abstract] [Full Text] [Related]

  • 5. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
    Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L.
    Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
    Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS, Müller J, Rupp NJ, Rüschoff JH, Eberli D, Donati OF.
    Radiology; 2019 Nov; 293(2):350-358. PubMed ID: 31502937
    [Abstract] [Full Text] [Related]

  • 7. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer.
    Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, Kua B, Samaratunga H, Delahunt B, Egevad L, Wong D, McEwan L, Brown N, Parkinson R, Esler R, Yaxley JW.
    J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
    [Abstract] [Full Text] [Related]

  • 8. Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI - What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?
    Skawran SM, Sanchez V, Ghafoor S, Hötker AM, Burger IA, Huellner MW, Eberli D, Donati OF.
    Eur J Radiol; 2022 Jan; 146():110044. PubMed ID: 34844173
    [Abstract] [Full Text] [Related]

  • 9. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology.
    Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, Dunglison N, Gardiner RA, Yaxley J.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):20-30. PubMed ID: 30229528
    [Abstract] [Full Text] [Related]

  • 10. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
    Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N.
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
    [Abstract] [Full Text] [Related]

  • 11. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 12. Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Vlachostergios PJ, Niaz MJ, Thomas C, Christos PJ, Osborne JR, Margolis DJA, Khani F, Bander NH, Scherr DS, Tagawa ST.
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [Abstract] [Full Text] [Related]

  • 13. Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.
    Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.
    J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
    [Abstract] [Full Text] [Related]

  • 14. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer.
    Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA.
    Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
    [Abstract] [Full Text] [Related]

  • 15. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA.
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic Accuracy of a Combination of Preoperative 68-Ga Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
    Simsek A, Celen S, Duran MB, Kucuker K, Yagci AB, Sen Turk N, Yuksel D, Turan T.
    Urol Int; 2024 Mar; 108(4):277-284. PubMed ID: 38479370
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
    Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T.
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [Abstract] [Full Text] [Related]

  • 18. Comparisons of mpMRI, 68Ga-PSMA PET/CT and mpMRI combined with 68Ga-PSMA PET/CT in diagnosing prostate cancer based on tumor detection, localization and staging.
    Mai Z, Zhu M, Feng T, Zhou Z, Zhou Y, Wang D, Yuan R, Xiao Y, Wang J, Sun H, Yan W.
    World J Urol; 2024 Jan 12; 42(1):29. PubMed ID: 38214793
    [Abstract] [Full Text] [Related]

  • 19. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L.
    BJU Int; 2020 Apr 12; 125(4):515-524. PubMed ID: 31957122
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy.
    Koseoglu E, Kordan Y, Kilic M, Sal O, Seymen H, Kiremit MC, Armutlu A, Ertoy Baydar D, Altinmakas E, Vural M, Falay O, Canda AE, Balbay D, Demirkol MO, Esen T.
    Prostate Cancer Prostatic Dis; 2021 Mar 12; 24(1):202-209. PubMed ID: 32826958
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.